This article was originally published in The Gray Sheet
Completes a $3 mil. private placement, carried out through the New York investment banking firm A. R. Baron & Co. Inc., that will allow the Irvine, California company to resume operations. Cardiac Science, which in May was forced to suspend its development of the Powerheart 360j automatic external cardioverter defibrillator due to a lack of funds, says it is nearing the end of its Phase I trials of the product. The financing, according to the company, will fund the completion of Phase I studies and the beginning of Phase II trials, slated for mid-1995
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.